GLP1 receptor agonists are gaining increasing recognition, not only for their metabolic benefits in type 2 diabetes, but also for potential effects beyond glycemic control. New experimental evidence suggests that GLP1 signaling may influence reward pathways in the brain, suggesting the possibility that these agents may alter behaviors related to substance use.
Autoren
- Jens Dehn
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- Psychedelic-assisted therapy
Current status of PAT
- First-line treatment for T2D
SGLT2i, metformin, or both?
- Biophilic Design of Work Environments
Effects on Health, Well-Being, and Productivity
- From symptom to diagnosis
Intrapelvic mass with an ambiguous differential diagnosis
- Endocrinology: APECED-Associated Hypoparathyroidism
A parathyroid hormone analog corrected serum calcium levels
- Transient ischemic attack
Comprehensive diagnostic testing can reduce the risk of stroke
- Malignant Tumors of the Clavicle
Surgical Challenges and Recurrence Patterns
- Chronic hand eczema: common, long-lasting, and distressing